Gilead Sciences Inc. (GILD) announced Friday morning that the majority of hepatitis C genotype 1 patients with a prior "null" response to an interferon-containing regimen enrolled in the ongoing ELECTRON study experienced viral relapse within four weeks of completing 12 weeks of treatment with GS-7977 plus ribavirin.
Gilead Sciences has gapped open sharply lower Friday and is now down 8.81 at $46.00 on above average volume. The stock has dropped below a range at the highs of the year and has set a one-month low.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.